Klin Farmakol Farm. 2012;26(1):39-42

Incretin-based therapy and the risk of acute pancreatitis

Ondřej Krystyník, Jaromíra Gajdová
2. interní klinika LF UP a FN Olomouc

Incretin-based therapy aids in achieving therapeutic goals in patients with type 2 diabetes mellitus. Gliptins and GLP-1 receptor agonists

represent two different concepts whose effect is based on the effect of incretin hormones, particularly GLP-1 (glucagon-like peptide-1).

Both drug groups reduce the levels of glycated haemoglobin and fasting as well as postprandial glycaemia. Gliptins have a neutral effect

on body weight while GLP-1 receptor agonists even reduce it. Both groups share a low risk of hypoglycaemic episodes during the course

of treatment. The potential risk of developing acute or chronic pancreatitis during incretin-based therapy is currently being discussed.

The present paper summarizes the basic knowledge published so far.

Keywords: acute pancreatitis, incretin-based therapy, GLP-1 analogs, DPP-4 inhibitors

Published: April 24, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krystyník O, Gajdová J. Incretin-based therapy and the risk of acute pancreatitis. Klin Farmakol Farm. 2012;26(1):39-42.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 2004; 287: E199-E206. Go to original source... Go to PubMed...
    2. Drucker DJ. The biology of incretin hormones. Cell Metab 2006; 3: 153-165. Go to original source... Go to PubMed...
    3. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 diabetes. Diabetologia. 1986; 29 (1): 46-52. Go to original source... Go to PubMed...
    4. Knop FK, Vilsboll T, Holst J. Incretin-Based Therapy of Type 2 Diabetes Mellitus. Current Protein and Peptide Science 2009; 10 (1): 46-55. Go to original source... Go to PubMed...
    5. Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evalution of the risk and benefits. Diabetes Care 2010; 33: 428-433. Go to original source... Go to PubMed...
    6. Buse JB, Rosenstock J, Sesti G, et al. LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47. Go to original source... Go to PubMed...
    7. Karasik A, Aschner P, Katzeff H, et al. Sitagliptin, a DPP4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008; 24: 489-496. Go to original source... Go to PubMed...
    8. Sekimoto M, Takada T, Kawarada Y, et al. JPN Guidelines for the management of acute pancreatitis: epidemiology, etiology, natural history, and outcome predictors in acute pancreatitis. J Hepatobiliary Pancreat Surg 2006; 13: 10-24. Go to original source... Go to PubMed...
    9. Trivedi CD, Pitchumoni CS. Drug-induced pancreatitis: an update. J Clin Gastroenterol 2005; 39 (8): 709-716. Go to original source... Go to PubMed...
    10. Vinklerová I, Urbánek K. Polékové akutní pankreatitidy u idiopatických střevních zánětů. Klin Farmakol Farm 2008; 22 (3): 110-112.
    11. Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care 2006; 29: 471. Go to original source... Go to PubMed...
    12. Ahmad SR, Swann J. Exenatide and rare adverse events. N Engl J Med 2008; 358: 1970-1971. Go to original source...
    13. US Food and Drug Administration (2007) Information for healthcare professionals: exenatide (marketed as Byetta) -10/2007. Dostupné na: http://www.fda.gov/.
    14. US Food and Drug Administration (2008) Information for healthcare professionals: exenatide (marketed as Byetta) -8/2008 Update. Dostupné na: http://www.fda.gov/.
    15. US Food and Drug Administration (2009) Information for healthcare professionals-acute pancreatitis and sitagliptin (marketed as Januvia and Janumet). Dostupné na: http://www.fda.gov/.
    16. Lee PH, Stockton MD, Franks AS. Acute pancreatitis associated with liraglutide. Ann Pharmacother 2011; 45 (4): e22. Go to original source... Go to PubMed...
    17. Girgis CM, Champion BL. Vildagliptin-induced acute pancreatitis. Endocr Pract. 2011; 17 (3): e48-50. Go to original source... Go to PubMed...
    18. Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, Braun DK, Noel RA, Seeger JD. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes, Obesity and Metabolism 2011; 13: 559-566. Go to original source... Go to PubMed...
    19. Engel SS, Williams-Herman DE, Golm GT, et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010; 64: 984-990. Go to original source... Go to PubMed...
    20. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler P. Pancreatitis, pancreatic and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011; 141: 150-156. Go to original source... Go to PubMed...
    21. European Association for the Study of Diabetes. EASD commentary on the publication by Elashoff, et al, published online in Gastroenterology, February 2011. Increased incidence of pancreatitis and cancer among patients given glucagon like peptide-1-based therapy. 2011. Dostupné na: www.easd.org/.
    22. Hawkes N (2011) Journal withdraws article after complaints from drug manufacturers. BMJ 342: d2335. Go to original source... Go to PubMed...
    23. BMJ News (2011) Replies to ''Journal withdraws article after complaints from drug manufacturers''. http://www.bmj.com/content/342/bmj.d2335.full/reply#bmj_el_256671.
    24. Raschi E, Piccini C, Poluzzi E, Marchesini G, De Ponti F. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetologica; published online: 19 October 2011. Go to original source...
    25. Banks PA. Epidemiology, natural history and predictors of disease outcome in acute and chronic pancreatitis. Gastrointest endosc 2002; 56: S226-S230. Go to original source... Go to PubMed...
    26. Yadav D, Lowenfels AB. Trends in the epidemiology of the first attack of acute pancreatitis: a systematic review. Pancreas 2006; 33: 323-330. Go to original source... Go to PubMed...
    27. Noel RA, Braun DK, Patterson RE, Bloomgren GL. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32: 834-838. Go to original source... Go to PubMed...
    28. Girman CJ, Kou TD, Cai B, Alexander CM, O´Neill EA, Williams-Herman DE, Katz L. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes, Obesity and Metabolism 2010; 12: 766-771. Go to original source... Go to PubMed...
    29. Keech A, Simes RJ, Barter P, et al. Effect of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861. Go to original source... Go to PubMed...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.